Capital Fund Management S.A. Cuts Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

Capital Fund Management S.A. reduced its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDPFree Report) by 37.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 25,027 shares of the company’s stock after selling 14,823 shares during the quarter. Capital Fund Management S.A. owned 0.08% of Medpace worth $7,672,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. RiverPark Advisors LLC purchased a new position in Medpace in the 4th quarter worth approximately $26,000. Contravisory Investment Management Inc. purchased a new position in shares of Medpace in the fourth quarter worth $26,000. GAMMA Investing LLC bought a new position in shares of Medpace during the fourth quarter valued at $30,000. McGlone Suttner Wealth Management Inc. purchased a new stake in shares of Medpace during the fourth quarter valued at $33,000. Finally, Principal Securities Inc. bought a new stake in Medpace in the 4th quarter worth about $68,000. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Price Performance

NASDAQ:MEDP opened at $405.68 on Tuesday. The firm has a market capitalization of $12.57 billion, a price-to-earnings ratio of 41.35, a price-to-earnings-growth ratio of 1.98 and a beta of 1.39. The business has a fifty day moving average price of $393.84 and a 200-day moving average price of $355.74. Medpace Holdings, Inc. has a one year low of $207.83 and a one year high of $421.00.

Medpace (NASDAQ:MEDPGet Free Report) last issued its quarterly earnings results on Monday, April 22nd. The company reported $3.20 EPS for the quarter, topping analysts’ consensus estimates of $2.45 by $0.75. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The business had revenue of $511.00 million during the quarter, compared to analysts’ expectations of $512.39 million. During the same quarter in the prior year, the business posted $2.27 earnings per share. The business’s quarterly revenue was up 17.7% on a year-over-year basis. On average, equities research analysts expect that Medpace Holdings, Inc. will post 11.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Medpace

In other news, Director Ashley M. Keating sold 250 shares of the firm’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $409.87, for a total transaction of $102,467.50. Following the sale, the director now directly owns 250 shares in the company, valued at approximately $102,467.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO August J. Troendle sold 15,102 shares of the business’s stock in a transaction that occurred on Monday, April 29th. The stock was sold at an average price of $400.69, for a total value of $6,051,220.38. Following the transaction, the chief executive officer now directly owns 791,541 shares of the company’s stock, valued at approximately $317,162,563.29. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Ashley M. Keating sold 250 shares of the stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $409.87, for a total transaction of $102,467.50. Following the sale, the director now directly owns 250 shares of the company’s stock, valued at $102,467.50. The disclosure for this sale can be found here. Insiders have sold 29,973 shares of company stock valued at $11,960,425 over the last 90 days. 20.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have issued reports on MEDP. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Medpace in a research note on Monday, March 18th. They set a “hold” rating and a $395.00 target price on the stock. UBS Group raised shares of Medpace from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $282.00 to $452.00 in a research report on Thursday, February 15th. Robert W. Baird boosted their target price on shares of Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a research note on Wednesday, April 24th. StockNews.com downgraded Medpace from a “buy” rating to a “hold” rating in a research note on Friday. Finally, TD Cowen assumed coverage on Medpace in a research report on Wednesday, May 29th. They set a “buy” rating and a $452.00 price objective for the company. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $443.14.

View Our Latest Research Report on MEDP

About Medpace

(Free Report)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Read More

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDPFree Report).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.